Carine Cleren

Dr. Carine Cleren


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NRNeeta S Roy
Neeta S Roy
CCCarine Cleren
Carine Cleren
SSShashi K Singh
Shashi K Singh
LYLichuan Yang
Lichuan Yang
MBM Flint Beal
M Flint Beal
SGSteven A Goldman
Steven A Goldman

24 October 2007 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
ASAndrew D. Strand
Andrew D. Strand
ZBZachary C. Baquet
Zachary C. Baquet
AAAaron K. Aragaki
Aaron K. Aragaki
PHPeter Holmans
Peter Holmans
LYLichuan Yang
Lichuan Yang
KJKevin R. Jones
Kevin R. Jones
Many pathways have been proposed as contributing to Huntington's disease (HD) pathogenesis, but generally thein vivoeffects of their perturbation have not been compared with reference data from human patients. Here we examine how accurately mechanistically motivated and genetic HD models recapitulate the striatal gene expression phenotype of human HD. The representative genetic model was the R6/2 transgenic mouse, which expresses a fragment of the huntingtin protein containing a long CAG repeat. Pathogenic mechanisms examined include mitochondrial dysfunction; profiled in 3-nitropropionic acid-treated rats, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, andPGC-1α knock-out mice; and depletion of brain-derived neurotrophic factor (BDNF) using heterozygous and forebrain-specific BDNF-knock-out mice (BDNFHET,Emx-BDNFKO). Based on striatal gene expression, we find the BDNF models, both heterozygous and homozygous knock-outs, to be more like human HD than the other HD models. This implicates reduced trophic support as a major pathway contributing to striatal degeneration in HD. Because the majority of striatal BDNF is synthesized by cortical neurons, the data also imply that cortical dysfunction contributes to HD's hallmark effects on the basal ganglia. Finally, the results suggest that striatal lesions caused by mitochondrial toxins may arise via pathways different from those that drive neurodegeneration in HD. Based on these findings, we present a testable model of HD pathogenesis that, unlike most models, begins to account for regional specificity in human HD and the absence of such specificity in genetic mouse models of HD.

1 March 2006 in Neurobiology of Disease
Verified
Journal Article
Closed access
Péter KlivényiPéter Klivényi
Péter Klivényi
DSDonald Siwek
Donald Siwek
GGGabrielle Gardian
Gabrielle Gardian
LYLichuan Yang
Lichuan Yang
ASAnatoly A. Starkov
Anatoly A. Starkov
MBM. Flint Beal
M. Flint Beal

30 June 2005 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
CCCarine Cleren
Carine Cleren
NCNoel Y. Calingasan
Noel Y. Calingasan
JCJunya Chen
Junya Chen
MBM. Flint Beal
M. Flint Beal
Oxidative stress and inflammation are implicated in neurodegenerative diseases including Parkinson's disease (PD) and Huntington's disease (HD). Celastrol is a potent anti‐inflammatory and antioxidant compound extracted from a perennial creeping plant belonging to theCelastraceaefamily.Celastrol is known to prevent the production of proinflammatory cytokines, inducible nitric oxide synthase and lipid peroxidation. Mice were treated with celastrol before and after injections of MPTP, a dopaminergic neurotoxin, which produces a model of PD. A 48% loss of dopaminergic neurons induced by MPTP in the substantia nigra pars compacta was significantly attenuated by celastrol treatment. Moreover, celastrol treatment significantly reduced the depletion in dopamine concentration induced by MPTP. Similarly, celastrol significantly decreased the striatal lesion volume induced by 3‐nitropropionic acid, a neurotoxin used to model HD in rats. Celastrol induced heat shock protein 70 within dopaminergic neurons and decreased tumor necrosis factor‐α and nuclear factor κ B immunostainings as well as astrogliosis. Celastrol is therefore a promising neuroprotective agent for the treatment of PD and HD.

31 October 2007 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
CCCarine Cleren
Carine Cleren
LYLichuan Yang
Lichuan Yang
BLBeverly Lorenzo
Beverly Lorenzo
NCNoel Y. Calingasan
Noel Y. Calingasan
ASAndrew Schomer
Andrew Schomer
MBM. Flint Beal
M. Flint Beal
J. Neurochem. (2008) 104, 1613–1621. Coenzyme Q10 (CoQ10) is a promising agent for neuroprotection in neurodegenerative diseases. We tested the effects of various doses of two formulations of CoQ10 in food and found that administration in the diet resulted in significant protection against loss of dopamine (DA), which was accompanied by a marked increase in plasma concentrations of CoQ10. We further investigated the neuroprotective effects of CoQ10, reduced CoQ10 (ubiquinol), and CoQ10 emulsions in the (MPTP) model of Parkinson’s disease (PD). We found neuroprotection against MPTP induced loss of DA using both CoQ10, and reduced CoQ10, which produced the largest increases in plasma concentrations. Lastly, we administered CoQ10 in the diet to test its effects in a chronic MPTP model induced by administration of MPTP by Alzet pump for 1 month. We found neuroprotective effects against DA depletion, loss of tyrosine hydroxylase neurons and induction of alpha‐synuclein inclusions in the substantia nigra pars compacta. The finding that CoQ10 is effective in a chronic dosing model of MPTP toxicity, is of particular interest, as this may be more relevant to PD. These results provide further evidence that administration of CoQ10 is a promising therapeutic strategy for the treatment of PD.

1 January 2004 in NeuroMolecular Medicine
Verified
Journal Article
Closed access
PDF file
GGGabriella Gardian
Gabriella Gardian
LYLichuan Yang
Lichuan Yang
CCCarine Cleren
Carine Cleren
NCNoel Y. Calingasan
Noel Y. Calingasan
Péter KlivényiPéter Klivényi
Péter Klivényi
MBM. Flint Beal
M. Flint Beal